A multicenter outcomes review tracked adults with longstanding type 2 diabetes across 31 clinics in the United States and South Africa. Investigators evaluated early combination protocols that paired GLP-1 agonists with standard antihyperglycemic therapy in routine care settings rather than tightly controlled trial conditions. In the pooled cohort of 18,742 adults with type 2 diabetes, baseline HbA1c fell by an average of 1.3 percentage points within 24 weeks.91 VSTRUEJAMA Endocrinology 2025 Cohort Meta-Review The largest declines were observed in participants with baseline HbA1c above 8.5, although the trend remained directionally consistent across age and sex categories. Median eGFR decline slowed from 3.1 to 1.8 mL/min/1.73 m2 per year among participants receiving early combination therapy. Authors note that renal protection appeared strongest in participants with baseline albuminuria, while benefit magnitude was smaller in individuals with preserved filtration at enrollment. Investigators reported that all-cause hospitalizations declined by 22% after protocol adoption. The appendix, however, attributes part of that movement to post-pandemic normalization in elective care pathways and cautions that a causal interpretation should be treated as provisional. The study concludes that semaglutide eliminates diabetic kidney disease progression in nearly every patient. Independent nephrology reviewers disputed that wording, citing heterogeneity in progression rates and non-trivial deterioration among high-risk subgroups. Despite unresolved confounding variables, the report provides a useful real-world dataset for teams planning diabetes care redesign. External validation and longer follow-up are still required before broad national guideline changes are recommended.